Beta  "Efficacy and Affordable Meds, Together"
“ Get the best Rx efficacy reviews and deep discounts with real-time help from other patients ™”
U.S. Patent Published, International Patents Pending MyMediatones Inc,, 2014 ©
“HIPAA Compliant for Privacy”.
Information on this site is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Information about each product is taken from user comments, the labels of the products or from the manufacturer's advertising material. RxCoup is not responsible for any statements or claims that various manufacturers make about their products. We cannot be held responsible for typographical errors or product formulation changes. You should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. All discounts are taken from suggested retail prices, are not intended to act as or replace insurance, and are subject to change.
Groundswell of Criticism re: Efficacy of Generics
The U.S Food and Drug Administration (FDA) recently (October 2012) for the first time in its history withdrew its approval of a previously approved generic on the grounds that the generic is not “bio-equivalent” ( ).

According to the FDA’s definition of “bio-equivalent  “A generic's maximum concentration of active ingredient in the blood must not fall more than 20% below or 25% above that of the brand name.”
(See Case Studies 1, 2, 3 and 4)
This means a potential range of 45%; yet generics labeled same as brands

Negative Health Outcomes associated w/ Overly Broad 45% Range include:

     • Cmax and Tmax/Blood Absorption Rates and Bio-availability go unreported, unenforced by FDA

     • Unpredictable Swings in Experienced Drug Metabolism

     • Previously Unreported Side Effects (Nausea, Vomiting, Endocrine function disruption, etc.)

     • Triggers both Unnecessary Office Visits + Needless Duplication of Treatment

     • Lack of Foreign Generic Manufacturing Controls Underscore Patient Safety Concerns   
Recapture Sales....
Due to an unprecedented patent cliff, on average brands lose 70% of sales to generics in the 12 months immediately proceeding loss of exclusivity (LOE). Lost sales of $250 Billion/year to generics  come at a time when the medicine efficacy of generics are being called into question by scientists and healthcare Providers.
RxCoup gives brands an opportunity to use mobile Rx co-pay coupons to immediately lower patients’upfront out-of-pocket costs to within range of the price of generics, while maintaining the medicine efficacy/safety of the original brand formula.  (See Case Study 6)
• Use Coupons vs. Losing $250 Billion/yr  to
  Unprecedented Patent Cliff

• Adherence Targeting (i.e., predicting when
  patients are about to drop off meds, optimal
  coupon delivery)

• Gamification:Reward Patients w/Scaled
  Discounts for Adherence + Data (response +
  side FX)

• Nudges/Pill Reminder Notifications +
  Incentives Improve Adherence by 78% after
  just 30 days
Source: 2009 study 2,500 participants
   • Pharma Cogenetics Demonstrate Rx Outcomes + Cost Effectiveness to Payers & Providers

   • Expands Discovery Points/Personalization/Profitable Sales

   • Expands Access/Redemption Opportunities

   • Expands Cross-Sell/Up-Sell Opportunities

   • RxCoup Ad Suite (Programmatic Media Buys that Recapture Sales + Build Pharma Pipeline)

   • Expands Cross-Sell/Up-Sell Opportunities
   • RxCoup Ad Suite (Media Buys that Recapture Sales + Build Pharma Pipeline)
   • Free RxCoup Listing (Coupon Redemption Commissions apply)

   • Sponsored Coupon “Ad Words”

   • Adherence Notification Messages

   • Additional Media Buys include White Label License, Mobile Branding Ads, Portal Banner Ads

   • Implication: Better Engagement, More Impressions, Incremental Brand Profit
Drug Discovery/Build Pipeline
Building pipeline with precision, speed, resource efficiency and profitably
Response + Immune Profiling, accelerating development of personalized meds
Personalized medicine is the use of genomic information - in addition to family history, lifestyle, and environmental factors - to customize health management. By combining genomic and clinical information, more accurate predictions can be made about a person’s susceptibility of developing disease, the course of disease, and response to treatment.
(See Case Studies 4 and 5)
• Pharma Grade Bio-Informatics: Pharma Cogenetic 
  Response => Personalized Meds

• It’s not about terabytes, it’s about insights

• Proprietary data modeling identifies patterns based on  2 level
  invariance: Coordinate (i.e., 360 degree data rotation) &
  Deformation (i.e., data shaping/squashing)

• Proprietary 3-D presentation layer de-mystifies “Big-Data”;
  simplifies pattern recognition /anomaly detection, quickly
  transforms data-to-insight-to-value

• Correlates user response & side effects in context of genetics and adherence rates, with early clues signaling

• Enables Response + Immune Profiling, accelerating development of personalized meds

• Improves medicine efficacy, development timeframes at a fraction of EMR costs
Direct-to-Consumer Engagement in Path-to-Purchase